Form 4 for SYRE Spyre Therapeutics, Inc.

Accepted 2026-03-03 00:00:00 ET · period of report 2026-03-02 · accession 0001636282-26-000026 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2026-03-03	2026-03-02	SYRE	Turtle Cameron	CEO, Dir	S - Sale	$42.19	-15.0K	651.6K	-2%	-$632.9K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-03-02	S	D	9,100	$42.49	642,540	D	—	—	(F4) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.23 to $42.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Includes 130,683 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
2	Common	Common Stock	2026-03-02	S	D	5,900	$41.73	651,640	D	—	—	(F2) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.23 to $42.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Includes 130,683 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.